Loading
Before investing in a full trial, give a few patients a tiny dose of a new compound and use scans and blood tests to see whether it reaches the tumour and hits its target. Fund these small studies as a matter of routine.
Phase 0 (exploratory IND) studies use microdoses or short courses to measure pharmacokinetics, target engagement (via PET tracers, tumour biopsies or pharmacodynamic markers) and biodistribution before committing to IND-enabling toxicology at full scale. They are cheap, fast and answer the question that kills most academic compounds late: does it get where it needs to go and do what it should in people? A dedicated fund pays for radiolabelling, tracer synthesis, phase 0 unit costs and biopsy-based pharmacodynamics for academic assets, with a rule that assets failing target engagement are dropped and published.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, Translational research: crossing the valley of death, The valley of death between lab and product.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, Lab models that fail to predict what happens in patients, The valley of death between lab and product.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares Translational research: crossing the valley of death, The valley of death between lab and product.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.